drugset / Trial / NCT03799120

Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms

NCT03799120

Phase 4 Unknown 80 enrolled Gundersen Lutheran Medical Foundation
RandomizedParallel-groupTriple-blindSupportive care

Summary

A single-center prospective, randomized study to assess two different dosing regimens (0.4 mg QD vs. 0.4 mg BID) of tamsulosin for ureteral stent-related discomfort will be completed.

Timeline

Start
2019-02-18
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamsulosin Other / unclassified 0.4 mg

Indications